Patient appointments
If creams are not enough, a clinician may discuss systemic treatment for plaque psoriasis. TREMFYA is one injectable option. A useful assessment considers affected sites, daily impact, previous treatment, safety and reliable ongoing access.
An appointment does not confirm access to a particular medicine, procedure or specialist. Ask the team about the care and coverage you need.
Medical information checked against current US sources: October 19, 2026.
The US label includes adults and children age six or older who weigh at least 40 kg and have moderate-to-severe plaque psoriasis for which systemic therapy or phototherapy is appropriate. It is not an approval for every type of psoriasis, eczema or an unexplained rash.
Bring dated skin photographs, prior prescriptions, treatment duration and reasons for stopping. Mention scalp, genital, palm, sole and nail problems, even if they occupy a small area. The diagnosis and treatment burden should be assessed together.
The recommended psoriasis dose is 100 mg under the skin at week 0 and week 4, then every eight weeks. This is different from the induction doses used for inflammatory bowel disease. Match the device and dose to the prescription and obtain training before any home administration.
Adults may self-inject after training under professional guidance. The label does not recommend pediatric self-administration. For a child, confirm who will give the injection and which device instructions apply.
Tell the clinician about morning stiffness, swollen joints, heel pain, a swollen whole finger or toe, or changes in function. These can call for a separate psoriatic-arthritis assessment. Clearer skin does not establish that joint inflammation is controlled.
Before treatment, plan TB evaluation, review infections and vaccinations, and discuss liver tests when clinically indicated. Share pregnancy plans, breastfeeding and every prescription or supplement. The choice should fit your medical history as well as your preference about injections.
Record plaques, itch, sleep and difficult-site symptoms. Psoriasis trials assessed skin response at week 16, but an individual result cannot be promised. Agree on a review point and what to do if the skin remains painful, treatment is difficult to administer or a new symptom develops.
Confirm the specialty pharmacy, authorization period and refill process. Drug cost, consultation, testing and any administration charge may be separate. Ask the Nao team about the appropriate assessment service rather than assuming every location stocks or administers TREMFYA.
No. Guselkumab is an IL-23-blocking biologic antibody. Its purpose and schedule differ from a corticosteroid injection. It still carries infection and other precautions and requires a clinician-directed plan.
The labeled schedule is 100 mg subcutaneously at weeks 0 and 4, then every eight weeks. Do not copy a Crohn’s or ulcerative-colitis induction schedule, which uses different doses. If a dose is delayed, contact the prescriber or pharmacy for instructions.
Describe those concerns during the psoriasis evaluation. The clinician should establish what is causing the symptoms and how to assess improvement. Difficult-site symptoms may need additional assessment or treatment; no page or before-and-after photograph can promise complete clearance.
Possibly, but the timing must be prescribed. Bring the exact previous medicine, last dose, reason for changing and any infection history. Do not overlap immune-active treatments or stop your current regimen based only on a comparison page.
Ask about device training, a demonstration and whether a trained caregiver or an appropriate administration service is available. Confirm the practical arrangement before medicine is shipped. An oral option such as ICOTYDE may also be worth discussing when its indication and safety requirements fit your situation.
Choose a service and clinic in the Nao booking app. Confirm appointment availability and the care you need with the team.